Biodexa Acquires Worldwide Licensing Rights for Tolimidone
Biodexa Pharmaceuticals has announced its acquisition of the rights to tolimidone, a potential diabetes treatment, from Adhera Therapeutics. Biodexa...
Phase 2 studies
Biodexa Pharma Shares Double After Licensing Deal for Tolimidone
Biodexa Pharmaceuticals shares have doubled to $5.90 after the company acquired the rights to tolimidone, a potential diabetes treatment,...
Ventyx Biosciences Shares Plummet After VTX958 Setback
Ventyx Biosciences, a clinical-stage biopharmaceutical company, saw its shares plummet over 80% and hit a new all-time low after...
Sage Therapeutics Gets FDA Orphan Designation for SAGE-718 in Huntington’s
Sage Therapeutics has received FDA orphan-drug designation for SAGE-718, a potential treatment for Huntington's disease. The biopharmaceutical company is...